TopAbstracts in Ovarian Cancer 07/02/2008 TopAbstracts in Ovarian Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer-reviewed...
Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine (Prudent Press Agency)---SOUTH SAN FRANCISCO, CA-- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, an oral chemotherapy agent...
Two New Herceptin-Containing Regimens Approved The FDA has approved two new regimens containing trastuzumab (Herceptin) for the adjuvant treatment of HER2 node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer.The first regimen, known as TCH ...
Peregrine initiates dosing in Phase II lung cancer trial The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients.The multi-center...
Mesothelioma: Outdated Trial Has Lessons for Future It's a frustrating situation that couldn't be foreseen: A long-term clinical trial is initiated comparing palliative care plus a standard chemotherapy regimen against palliative care alone, but during the trial a new standard-of-care regimen...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell -- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and Paclitaxel -- TUSTIN, Calif., June 30, 2008 /PRNewswire-FirstCall/ -- Peregrine...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell -- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and Paclitaxel -- TUSTIN, Calif., June 30, 2008 /PRNewswire-FirstCall/ -- Peregrine...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM - News) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, (News) Inc.today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in...
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in...
TopAbstracts in Head and Neck Cancer 06/26/2008 Recent news - Head and Neck Cancer NICE Issues Guidance on Cetuximab Use in Head and Neck Cancer- (DGNews) Researchers Evaluate the Role of Chemotherapy at the End of Life- (DGNews) TopAbstracts in Head and Neck Cancer 06/12/2008- (DGNews)...
Oncolytics Biotech Inc. Announces U.S. Phase II Clinical Trial Investigating REOLYSIN® In Combination With Oncolytics Biotech Inc.('Oncolytics') announced recently that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical trial using intravenous administration of REOLYSIN in...
Unknown primary cancer sites In 2005 cancers of unknown primary site (CUP) represented around 4% of all new cases in New South Wales.However, these CUPs were the third most common cause of cancer death after lung and bowel cancer in NSW, which represented 8% of all...
Peripheral Neuropathy Therapy: Findings in peripheral neuropathy therapy reported from University of Californi Findings in peripheral neuropathy therapy reported from University of California, Division of Neuroscience (NewsRx.com) -- A new study, 'Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful...
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Com CALGARY, June 20 /CNW/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical trial using...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical trial using intravenous...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY 'REOLYSIN(R) is one of the more exciting targeted agents under development in oncology,' said Dr.Frank Giles This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa Oncolytics Biotech Inc.Announces U.S.
Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
('Oncolytics') announced...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical trial using intravenous...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical...
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Pa CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that following U.S.
Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Phase 2 clinical...
